Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C; GFPC 08–2015 ENERGY investigators. Léna H, et al. Among authors: demontrond p. Lancet Respir Med. 2024 Oct 29:S2213-2600(24)00264-9. doi: 10.1016/S2213-2600(24)00264-9. Online ahead of print. Lancet Respir Med. 2024. PMID: 39486424
Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.
Hoang TCT, Debieuvre D, Bravard AS, Martinez S, Le Garff G, Jeandeau S, Petit L, Marquette D, Amrane K, Demontrond P, Tiercin M, Jarjour B, Turlotte A, Masson P, Jaafar M, Hauss PA, Morel H; Study Group KBP-2020-CPHG. Hoang TCT, et al. Among authors: demontrond p. ESMO Open. 2024 Jun;9(6):103594. doi: 10.1016/j.esmoop.2024.103594. Epub 2024 Jun 7. ESMO Open. 2024. PMID: 38848661 Free PMC article.
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S, Guisier F, Curcio H, Ricordel C, Demontrond P, Abdallahoui S, Baloglu S, Greillier L, Chouaid C, Schott R. Nannini S, et al. Among authors: demontrond p. Curr Oncol. 2024 Mar 21;31(3):1656-1666. doi: 10.3390/curroncol31030126. Curr Oncol. 2024. PMID: 38534959 Free PMC article.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaïd C, Guisier F. Dhamelincourt E, et al. Among authors: demontrond p. Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15. Target Oncol. 2023. PMID: 37966566
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Among authors: demontrond p. Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7. Cancer Immunol Immunother. 2023. PMID: 36847863 Free PMC article. No abstract available.
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Among authors: demontrond p. Cancer Immunol Immunother. 2023 Jun;72(6):1881-1890. doi: 10.1007/s00262-022-03359-2. Epub 2023 Jan 24. Cancer Immunol Immunother. 2023. PMID: 36690799 Free PMC article.
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Debieuvre D, et al. Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36108315 Free PMC article.
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.
Césaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P, Balosso J, Chevalier F. Césaire M, et al. Among authors: demontrond p. Cancers (Basel). 2022 Jun 8;14(12):2829. doi: 10.3390/cancers14122829. Cancers (Basel). 2022. PMID: 35740495 Free PMC article. Review.
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A, Foll M, Brevet M, Antoine M, Novello S, Mondet J, Cadranel J, Girard N, Giaj Levra M, Demontrond P, Audigier-Valette C, Letouzé E, Lantuéjoul S, Fernandez-Cuesta L, Moro-Sibilot D. Mc Leer A, et al. Among authors: demontrond p. Lung Cancer. 2022 May;167:98-106. doi: 10.1016/j.lungcan.2022.01.008. Epub 2022 Jan 22. Lung Cancer. 2022. PMID: 35183375